alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 3,476–3,500 of 3,821 studies published 2025 (page 140 of 153) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Dementia in primary care: a qualitative study with general practitioners and caregivers with and without migration backgrounds

✓ Peer-reviewed alzhub usefulness score 32 out of 100. BMC Family Practice 2025-09-16

The analysis revealed six main themes: 'Core health care challenges,' 'communication approaches and information sharing,' 'role of GP,' 'situation of caregivers,' 'influence on caregiver-GP relationship,' and 'socio-cultural barriers and care preferences'. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Qualitative Evaluation of an Online Technology to Support Rural Caregivers of People with Dementia

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Geriatrics 2025-12-05

Key barriers included limited digital literacy, resistance to technology and privacy concerns, as well as competing organisational priorities, and inadequate technological infrastructure. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Employment Status, Decision-Making, and Sleep Among Hispanic and Latinx Dementia Family Caregivers: A Secondary Data Analysis

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Western Journal of Nursing Research 2025-06-16

Participants had a mean age of 55.1 years (SD = 14), were predominantly female, and primarily cared for a parent. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Emerging Trends in Early Dementia Diagnosis: An Analysis on Advanced Machine Learning Approaches

✓ Peer-reviewed alzhub usefulness score 32 out of 100. ACM Computing Surveys 2025-08-28

Dementia is the waning of cognitive abilities, which is typically seen with the natural aging process and includes issues with memory, language, and problem-solving abilities. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Digital Health Literacy and Physical Activity Programme for Improvement of Quality of Life in Caregivers of People with Dementia (CAREFIT): Study Protocol

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Healthcare 2025-05-22

The proposed protocol for the CAREFIT programme represents an innovative and multidisciplinary initiative that leverages a digital platform to promote the well-being of informal caregivers of people with dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Health Awareness and Dementia Risk Among Older Adults with Hypertension and Diabetes: A Cross-sectional Study in Thailand

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Iranian Journal of Psychiatry and Behavioral Sciences 2025-08-06

Participants exhibited strong awareness of the risks associated with complications and the severity of chronic diseases. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A review of studies on vascular dementia and iron metabolism

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Science Progress 2025-10-01

Vascular dementia (VaD) is recognized as the second most prevalent form of dementia after Alzheimer's disease, with its pathogenesis intricately associated with cerebrovascular pathologies, including chronic hypoperfusion, oxidative stress, and neuroinflammation. 2 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Nanocarrier-based drug delivery for mild cognitive impairment: Extracellular vesicles and carbon nanotubes as emerging therapeutic tools

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Biomedicine & Pharmacotherapy 2025-08-07

Mild cognitive impairment (MCI) is the in-between stage between healthy cognitive aging and neurodegenerative diseases such as Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development of small molecules promoting tau degradation in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Alzheimer s & Dementia 2025-12-01

Within around 700 new designed PROTACs, we found by computational modelling more than 25 PROTACs that were predicted to have a better ability to form ternary complexes than the previously reported PROTACs. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The evolving roles of imaging and fluid biomarkers for Alzheimer disease over the past quarter century

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Alzheimer s & Dementia 2025-12-01

In 2004, the first radiotracer that bound amyloid plaques was reported, which enabled visualization of the amount and regional distribution of amyloid plaques in the brains of living individuals via positron emission tomography (PET). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comment on “Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US”

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Alzheimer s & Dementia 2025-05-01

Letter in response to the article by Wang et al. recently published in Alzheimer's & Dementia (Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The impact of moxibustion on brain function in vascular dementia: a neuroimaging study involving amplitude of low-frequency fluctuations and functional connectivity

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Frontiers in Neurology 2025-12-18

Object On the basis of determining the clinical effect of moxibustion on vascular dementia (VD), this study explored the central mechanism of moxibustion on VD through fMRI. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive Activity From Early to Late Life and the Risk of AD Dementia

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Neurology Open Access 2025-01-10

Participation in late-life cognitive activities has been associated with a slower rate of cognitive decline and reduced risk of dementia; however, whether this association is independent of earlier experiences is unclear. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Deposition of aggregated cystatin C-amyloid-β complexes and reduced cathepsin B activity modulate cerebral amyloid angiopathy pathogenesis

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Journal of Neuropathology & Experimental Neurology 2025-12-17

Cystatin C (CST3) colocalizes with amyloid-β (Aβ) around vessels in cerebral amyloid angiopathy (CAA). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

TDP-43 proteinopathy: the complex biological and clinical findings in LATE-NC, LANS, and other mixed age-related major neurocognitive disorders

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Current Opinion in Psychiatry 2025-07-15

Since the term limbic-predominant age-related TDP-43 encephalopathy (LATE) was coined in 2019, more than 200 articles addressing the subject were published. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Transactive response DNA-binding protein 43 (TDP-43) proteinopathy: the complex biological and clinical findings in limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes, limbic-predominant amnestic neurodegenerative syndrome, and other mixed age-related major neurocognitive disorders

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Current Opinion in Psychiatry 2025-07-16

As the term limbic-predominant age-related transactive response DNA-binding protein 43 (TDP-43) encephalopathy (LATE) was coined in 2019, more than 200 articles addressing the subject were published. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Neuroinflammation and progress in clinical trials for the treatment of Alzheimer’s disease and related dementias: An update

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Innovative Medicines & Omics 2025-03-28

According to the latest report in 2024 by the World Health Organization, based on global data from 2021, Alzheimer’s disease (AD) and other forms of dementia rank seventh among the leading causes of death worldwide, with an estimated 1.8 million deaths. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Acupuncture reduces neuroinflammation and apoptosis, regulates peripheral immunity, and modulates T-cell subset distribution in vascular dementia rats

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Chinese Medicine 2025-11-25

Acupuncture ameliorated cognitive impairment in VD rats, reduced hippocampal neuronal damage and apoptosis, downregulated pro-apoptotic proteins (cleaved-caspase 3 and Bax), and upregulated anti-apoptotic Bcl-2. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Role of prion protein in mediating the synaptotoxic effects of tau oligomers: Implications for Alzheimer’s disease and related tauopathies

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Neural Regeneration Research 2025-08-13

We recently confirmed and extended these findings using recombinant TauOs generated from full-length human tau in the presence of arachidonic acid (Balducci et al., 2025; Figure 1). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed